Vertex Pharmaceuticals Inc released corrected data involving its cystic fibrosis treatments on Tuesday that lowered the number of patients who showed certain levels of improved lung function, sending its ...
Vertex Pharmaceuticals Incorporated (VRTX) announced today that a combination therapy of two of its drugs used for treating cystic fibrosis has yielded statistically favorable results in its late-stage clinical trials. Upon approval, it would be marketed to treat cystic fibrosis, a genetic condition that afflicts 30,000 US residents, and about 75,000 people around the world.
Vertex (VRTX) reported interim data on a Phase II study targeting Cystic Fibrosis, which affects 30,000 in the United States and 70,000 worldwide. Previously, the company's KALYDECO drug - which won FDA approval in January - could only be used to treat about 4% of those patients.
By Small Pharma Analyst:Vertex (VRTX) is a 25-year old biopharma company that has had more than its share of ups and downs over the years - and yet another company-defining event is just around the corner.